POPULATION 1 Koshy et al Retrospective MC Patients with stage I NSCLC who did not undergo Intervention: SBRT Overall survival: not defined (calculated with (2015) cohort study with surgery Kaplan-Meier method) Dose and fractions NR propensity-matched USA N = 13,036 (NR lesions) subgroup analysis Size: NR Comparator: Conventional radiotherapy Level III-1/III-2 Males 6531 (50%): Females 6505 (50%) Minimum 60 Gy in 30 fractions Risk of bias: Moderate Age 18–59 (8.5%), 60–69 (22.5%), 70–79 (40%), 85+ Median 21 (IQR 11–43) (29%) years Comparator: No treatment months Prior therapy: NR Price et al RCT OL MC Patients with stage IA-IIB NSCLC, age 18+, unfit for Intervention: Radical radiotherapy Overall survival: Actuarial survival for 1-year (2012) resection, performance status ≤ 2, no prior and 2-year rates. Survival curve shown Level II “majority” had 55 Gy in 20 fractions over 4 weeks treatment, no other malignancy in previous 5 (calculated with Kaplan-Meier method) UK Risk of bias: Moderate Comparator: Radical radiotherapy + chemo years, not pregnant or breast feeding Progression- or event-free survival: patients at Follow-up NR “majority” had 55 Gy in 20 fractions over 4 weeks N = 56 (NR lesions) [intervention] the end of the trial that were alive and had not plus gemcitabine progressed - "progression" was note defined N = 55 (NR lesions) [comparator] (calculated with Kaplan-Meier method) Median size 38 (3–89) mm [intervention] Adverse events: CG-CTC v2.0 (assumed same Median size 30 (3–55) mm [comparator] as CTCAE from other studies Males 38 (68%): Females 18 (32%) [intervention] Males 32 (58%): Females 23 (42%) [comparator] Median age 75 (range 49–88) years [intervention] Median age 74 (range 58–88) years [comparator] Prior therapy: NR
POPULATION 1 Koshy et al (2015) USA Retrospective MC cohort study with propensity-matched subgroup analysis Level III-1/III-2 Risk of bias: Moderate Median 21 (IQR 11–43) months Patients with stage I NSCLC who did not undergo surgery N = 13,036 (NR lesions) Size: NR Males 6531 (50%): Females 6505 (50%) Age 18–59 (8.5%), 60–69 (22.5%), 70–79 (40%), 85+ (29%) years Prior therapy: NR Intervention: SBRT Dose and fractions NR Comparator: Conventional radiotherapy Minimum 60 Gy in 30 fractions Comparator: No treatment Overall survival: not defined (calculated with Kaplan-Meier method) Price et al (2012) UK RCT OL MC Level II Risk of bias: Moderate Follow-up NR Patients with stage IA-IIB NSCLC, age 18+, unfit for resection, performance status ≤ 2, no prior treatment, no other malignancy in previous 5 years, not pregnant or breast feeding N = 56 (NR lesions) [intervention] N = 55 (NR lesions) [comparator] Median size 38 (3–89) mm [intervention] Median size 30 (3–55) mm [comparator] Males 38 (68%): Females 18 (32%) [intervention] Males 32 (58%): Females 23 (42%) [comparator] Median age 75 (range 49–88) years [intervention] Median age 74 (range 58–88) years [comparator] Prior therapy: NR Intervention: Radical radiotherapy “majority” had 55 Gy in 20 fractions over 4 weeks Comparator: Radical radiotherapy + chemo “majority” had 55 Gy in 20 fractions over 4 weeks plus gemcitabine Overall survival: Actuarial survival for 1-year and 2-year rates. Survival curve shown (calculated with Kaplan-Meier method) Progression- or event-free survival: patients at the end of the trial that were alive and had not progressed - "progression" was note defined (calculated with Kaplan-Meier method) Adverse events: CG-CTC v2.0 (assumed same as CTCAE from other studies
1403%20-%20Final%20Contracted%20Assessment%20Report%20(ACCESSIBLE).docx